The announcement of a new stock offering can have a mixed impact on a company's stock price. On one hand, it provides the company with necessary capital for its operations and development programs, which is positive. On the other hand, it dilutes existing shareholders' equity, which can be perceived negatively. Given Jasper's use of proceeds for advancing its clinical and preclinical programs, the impact is considered neutral in the short term as the benefits of funding development may balance out dilution concerns.